Zhejiang Gongdong Medical Technology's declining ROCE and sales trends are worrisome, particularly as the company is using more capital than five years ago. Despite this, the stock has given a 4.7% return to shareholders in the last three years. If these trends continue, better investment opportunities may exist elsewhere.

Despite the low ROE, Zhejiang Gongdong Medical Technology has posted impressive earnings growth due to heavy reinvestment into its business. The company's earnings are expected to accelerate according to the latest industry analyst forecasts.